A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

Type of Cancer
Lymphoma

Site
Bethesda

Sponsor
TG Therapeutics, Inc

Protocol Number
UTX-TGR-304

To Learn More Call
201-510-0910